Archive


Category: ~ $3.05B

  • Horizon Therapeutics to Acquire Viela Bio for ~ $3.05B

    Shots: Horizon to acquire Viela Bio for $53/ share, representing an equity value of $3.05B with a 53% premium over a closing price to Viela’s on Jan 29, 2020. Additionally, AstraZeneca to divest its 26.7% ownership in Viela Bio in an exchange of ~$760 – $780M The transaction expected to close in Q1’21. The acquisition […]